Jack Allen
Stock Analyst at Baird
(1.49)
# 3,850
Out of 5,124 analysts
42
Total ratings
41.18%
Success rate
-9.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $48.74 | -9.73% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $13.16 | +386.32% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.61 | +160.30% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.14 | +250.88% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.69 | +432.54% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $10.97 | +264.63% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $68.10 | +55.65% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $12.28 | +46.58% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $7.77 | +2,216.60% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.42 | +1,784.57% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $31.98 | +162.66% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.70 | +194.12% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.57 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.68 | +144.57% | 1 | Oct 7, 2021 |
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $48.74
Upside: -9.73%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $13.16
Upside: +386.32%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.61
Upside: +160.30%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.14
Upside: +250.88%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.69
Upside: +432.54%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $10.97
Upside: +264.63%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $68.10
Upside: +55.65%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $12.28
Upside: +46.58%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $7.77
Upside: +2,216.60%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.42
Upside: +1,784.57%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $31.98
Upside: +162.66%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.70
Upside: +194.12%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.68
Upside: +144.57%